Krystal Biotech
KRYS
12 hedge funds and large institutions have $31M invested in Krystal Biotech in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.77% less ownership
Funds ownership: 31.6% → 29.84% (-1.8%)
8% less funds holding
Funds holding: 13 → 12 (-1)
9% less capital invested
Capital invested by funds: $34M → $31M (-$3.01M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$739K |
| 2 |
BlackRock
New York
|
+$65.4K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$18.4K |
| 4 |
KBC Group
Brussels,
Belgium
|
+$12.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.01M |
| 2 |
Goldman Sachs
New York
|
-$232K |
| 3 |
Squarepoint
New York
|
-$114K |
| 4 |
Millennium Management
New York
|
-$79.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Fidelity Investments
Boston,
Massachusetts
| $12.1M | – | – | – |
|
|
RCM
2
RA Capital Management
Boston,
Massachusetts
| $5M | -$2.01M | -203,929 | -29% |
|
|
HCM
3
Highbridge Capital Management
New York
| $3.03M | – | – | – |
|
|
KCM
4
Knoll Capital Management
Miami,
Florida
| $3.03M | – | – | – |
|
|
TCP
5
Tourbillon Capital Partners
New York
| $2.55M | – | – | – |
|
|
BBA
6
Baker Bros. Advisors
New York
| $2.02M | – | – | – |
|
|
AG
7
Artal Group
Luxembourg
| $1.51M | – | – | – |
|
|
8
Vanguard Group
Malvern,
Pennsylvania
| $1.5M | +$739K | +75,009 | +101% |
|
|
9
Millennium Management
New York
| $174K | -$79.6K | -8,070 | -32% |
|
|
10
BlackRock
New York
| $75K | +$65.4K | +6,636 | +833% |
|
|
11
KBC Group
Brussels,
Belgium
| $22K | +$12.1K | +1,225 | +123% |
|
|
12
Acadian Asset Management
Boston,
Massachusetts
| $19K | +$18.4K | +1,871 | New |
|
|
13
Goldman Sachs
New York
| – | -$232K | -22,036 | Closed |
|
|
14
Squarepoint
New York
| – | -$114K | -10,800 | Closed |
|
KRYS Hedge Fund Activity: Q1 2018 in Review
12 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q1 2018, worth a combined $31M — down 8.8% from $34M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of KRYS and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $739K. The largest seller was RA Capital Management, cutting an estimated $2.01M.
- 12 institutional investors held Krystal Biotech (KRYS) as of Q1 2018, down from 13 in Q4 2017.
- Funds reported $31M of Krystal Biotech stock for Q1 2018, down 8.8% quarter-over-quarter.
- 1 fund opened new Krystal Biotech positions in Q1 2018 and 2 closed out, a net change of -1 holder.
- The largest Krystal Biotech buyer in Q1 2018 was Vanguard Group, an estimated $739K added.
- The largest Krystal Biotech seller in Q1 2018 was RA Capital Management, an estimated $2.01M sold.
Based on aggregated 13F filings for Q1 2018.